Composition of 5-nitrobenzoate derivatives as anti-metastatic agent that inhibits tumor cell-induced platelet aggregation

US9956191B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9956191-B2
Application numberUS-201715451426-A
CountryUS
Kind codeB2
Filing dateMar 7, 2017
Priority dateJul 9, 2012
Publication dateMay 1, 2018
Grant dateMay 1, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of inhibiting tumor cells-induced platelet aggregation and/or metastasis of the tumor comprising administrating to a subject in need thereof an effective amount of a 5-nitrobenzoate derivative of formula (I), wherein, R is a benzoyl optionally having a substituent selected from the group consisting of fluoro, chloro, bromo, iodo and methyl. 2. The method of claim 1 , wherein the subject is a mammal. 3. The method of claim 2 , wherein the subject is a human.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title

  • Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

  • from amides by reaction at nitrogen atoms of carboxamide groups · CPC title

  • having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9956191B2 cover?
Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platel…
Who is the assignee on this patent?
Univ Chang Gung
What technology area does this patent fall under?
Primary CPC classification A61K31/166. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).